Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240732 | 0.81 | NPC1 (0.38) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL12385779 | 0.80 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL4757549 | 0.79 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL18733292 | 0.78 | NAMPT (0.41) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL14009858 | 0.77 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL12384428 | 0.76 | ALDH1A1 (0.40) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL4756935 | 0.76 | ALDH1A1 (0.40) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL2639873 | 0.75 | ALDH1A1 (0.38) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL2421426 | 0.73 | HPGD (0.33) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL16528331 | 0.73 | HPGD (0.33) | ALDH1A1LMNAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | ALDH1A1 3412/4885LMNA 4742/4885KMT2A 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.